TeneoBio’s anti-cancer drugs showed encouraging early signs of efficacy in clinical trials. AbbVie likes the results very much and can exercise the right to choose Get it, So that the pharmaceutical giant has a way to keep up with the popular protein target chasing multiple myeloma.
AbbVie is paying an undisclosed amount to acquire TeneoOne, a subsidiary of TeneoBio headquartered in Newark, California, which is developing the TNB-383B drug. In 2019, the North Chicago-based pharmaceutical giant paid $90 million in advance to acquire TeneoOne as an exclusive option, which is responsible for the development of the drug through the first phase of testing.
Multiple myeloma, Plasma cell carcinoma, causes tumors to form in the bones of the body. The goal of several companies is to treat this disease with drugs that combat B cell maturation antigen (BCMA), a protein that is abundant in multiple myeloma cells. TNB-383B is a bispecific antibody that can attack two cancer proteins, BCMA and CD3. The drug is designed to guide the immune system to target tumors that express BCMA.
The phase 1 dose escalation trial of TNB-383B is ongoing, but based on the interim results reported by AbbVie and TeneoBio in 103 patients, the overall response rate for treatment with the drug was 79%. Among patients given doses of 40 mg or greater, the complete response to treatment was 29%. The results were reported in 24 patients, and the median follow-up time was 6.1 months. It is too early to report the median duration of the response. The most common adverse events reported in the study included an immune response called cytokine release syndrome, fatigue, and abnormally low levels of a type of white blood cell called neutrophils.
first of all Last August, GlaxoSmithKline approved a BCMA targeted therapy for BlenrepThe drug is an antibody-drug conjugate, a drug that attaches a tumor-killing payload to a targeted antibody. March, Bristol-Myers Squibb has won Abecma’s regulatory approval, A cell therapy called CAR T cell therapy, which is made by modifying the patient’s own immune cells. BMS drugs target BCMA, as are the cell therapies being developed by Johnson & Johnson and Novartis. Amgen’s BCMA targeting drug candidate is a bispecific T cell conjugant.
GSK and BMS multiple myeloma drugs are respectively approved for the treatment of patients whose disease does not respond to fourth-line therapy. AbbVie plans to develop TNB-383B for those who have received three early treatments. The company also believes that intravenous TeneoBio drugs have the advantage of lower dosing frequency. Other BCMA and CD3 bispecific therapies must be performed once a week. In a prepared statement, AbbVie vice chairman and president Michael Severino stated that the phase 2 clinical trial of TNB-383B will test a 60 mg dose every three weeks.
Photo by AbbVie